RhumbLine Advisers’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

RhumbLine Advisers’s Portfolio TBRA Stock Details TBRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-8,341	Closed	-$331K	–	2890
2016 Q3	$331K	Buy	+8,341	New	+$93.1K	﹤0.01%	2427
2015 Q2	–	Sell	-2,048	Closed	-$22K	–	3150
2015 Q1	$22K	Buy	2,048 +666	+48%	+$7.15K	﹤0.01%	3018
2014 Q4	$11K	Sell	1,382 -155	-10%	-$1.33K	﹤0.01%	3012
2014 Q3	$16K	Buy	1,537 +164	+12%	+$3.24K	﹤0.01%	2972
2014 Q2	$84K	Buy	+1,373	New	+$83.5K	﹤0.01%	2982

RhumbLine Advisers's TBRA Position: Q4 2016 in Review

RhumbLine Advisers sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2016, closing a stake of 8,341 shares — an estimated $331K sold.

RhumbLine Advisers first reported a position in TBRA in Q2 2014 and held it in 5 quarters. The position peaked at $331K in Q3 2016. 0 funds tracked by Wall St. Rank hold TBRA as of Q4 2016.

RhumbLine Advisers reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
RhumbLine Advisers sold 8,341 Tobira Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $331K.
RhumbLine Advisers first reported a position in Tobira Therapeutics, Inc. Common Stock in Q2 2014 and held it in 5 quarters.
RhumbLine Advisers's Tobira Therapeutics, Inc. Common Stock position peaked at $331K in Q3 2016.
0 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2016.

Based on RhumbLine Advisers's 13F filing for Q4 2016, filed 27 Jan 2017.